Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Partner Therapeutics' Bizengri (zenocutuzumab-zbco) gains FDA label expansion for NRG1 fusion-positive cholangiocarcinoma based on Ph1/Ph2 data
Antibody, cancer, bispecific antibody, cholangiocarcinoma, NRG1 fusion, HER2/HER3 target - Read more

argenx's VYVGART (efgartigimod alfa-fcab) receives FDA label expansion for all adult generalized myasthenia gravis serotypes
Protein therapy, autoimmune, monoclonal antibody, generalized myasthenia gravis, FcRn antagonist, efgartigimod - Read more

Genentech's Ocrevus (ocrelizumab) receives FDA approval for pediatric relapsing-remitting multiple sclerosis in patients aged 10 and older
Antibody, autoimmune, monoclonal antibody, multiple sclerosis, pediatric patients, CD20 target - Read more

Knight Therapeutics' TAVALISSE (fostamatinib) receives Brazil ANVISA approval for chronic immune thrombocytopenia in adults
Small molecule, autoimmune, SYK inhibitor, immune thrombocytopenia - Read more

NICE recommends Johnson & Johnson's RYBREVANT plus chemotherapy for EGFR exon 20 NSCLC via Cancer Drugs Fund
Monoclonal antibody, oncology, regulatory, managed access - Read more

Science 2 Sales builds and runs the entire outbound engine (across email, LinkedIn, and cold calling) for companies selling into biotech & pharma - so your sales team stops researching and starts closing qualified meetings with the decision-makers who can actually sign.

When it comes to outbound lead gen - you get the meetings. We handle everything else.

Learn more and book a free strategy call on our website.

LenioBio, Twist Bioscience partner to accelerate AI-designed protein wet-lab validation using ALiCE platform
Research collaboration, AI/ML, drug discovery, antibody, cell-free expression - Read more

Raynovent Biotech's ZSP1601 meets primary endpoint in Ph2b trial for metabolic dysfunction-associated steatohepatitis
Small molecule, metabolic, pan-PDE inhibitor, MASH, liver fibrosis - Read more

Gilead raises Yeztugo 2026 sales target to $1B after strong launch trajectory
Small molecule, infectious disease, revenue impact, CAR-T, oncology - Read more

Gilead raises 2026 sales outlook after strong HIV growth, despite expected earnings hit from $11.5B acquisition spending
Cell therapy, oncology, major transaction, financial, strategic - Read more

Artiva Biotherapeutics prices $300M offering of common stock and pre-funded warrants, autoimmune cell therapies
Cell therapy, autoimmune, clinical-stage - Read more

Quantinuum plans IPO to fund quantum computing platform for drug discovery
Quantum computing, AI/ML platform, drug discovery, platform technology - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Daiichi Sankyo takes $610M profit hit from ADC manufacturing overcapacity amid shifting demand forecasts
Antibody-drug conjugate, oncology, operational, financial, cost reduction - Read more

Capricor Therapeutics sues US partner NS Pharma for breach of contract over deramiocel launch failures
Cell therapy, rare disease, operational, financial - Read more

Biogen, Eisai face 3-month FDA delay for subcutaneous Leqembi (lecanemab) initiation in Alzheimer's disease
Antibody, neurological, monoclonal antibody, Alzheimer's disease, amyloid, subcutaneous delivery - Read more

Trump expected to remove FDA Commissioner Marty Makary amid leadership turmoil, reports say
Leadership change, regulatory, operational, strategic - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here